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swab) nucleotide difference in VP1 compared with the Sabin
strain. These results conﬁrm the presence of an iVDPV1. The
sequences of 5ˇıNCR showed the 480 nucleotide change, prov-
ing the reversion of the sabin strain to the infectivity. These
ﬁndings were sent to the National Program in less than 15
days.
Results: After the detection of AFP notiﬁcation was sent
to the ﬁeld, Epidemiology actions were made as in all cases.
In the investigation three different locations were estab-
lished as the child residence. All of them were visited and
vaccination of all children under 18 years old was done. A
national and international alert were sent Active community
surveillance was made and contact and environmental sam-
ples were collected and sent to the Regional Lab. In none
of them the iVDPV 1 was detected. Four serial samples from
the case were taken each month, in all of them the same
iVDPV1 was isolated.
Conclusion: The country has sustained the surveillance
of AFP through 22 years based on the collaborative work
between the laboratory and the epidemiologists. No other
cases appeared although the vaccine coverage in one of
the district was very low. As consequence of this ﬁnd-
ing a national vaccination campaign was made. Although
poliomyelitis is a threat to the region Argentine is ready to
face it.
doi:10.1016/j.ijid.2010.02.628
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Background: The acronym ESAVI deﬁnes any clinical pic-
ture after vaccination chronologically related to its use.
Further analysis of the event determines the role of the
vaccine in its causality. In the case of YFV, three cate-
gories of severe adverse events are described: anaphylactic
reactions, YF neurotropic disease (YFV-AND), viscerotropic
disease (YFV-AVD). YFV is included in Argentinaˇıs national
immunization program for use in population older than
one year of age in regions with transmission risk. It is
also prescribed to travelers to endemic zones and can be
required upon International Health Regulation allowance.
We describe the clinical, epidemiological and laboratory
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roﬁle of ESAVIs in the context of an extraordinarily
ncreased YFV administration in Argentina in 2008, due to
eported fatal cases involving humans and monkeys in risk
ones.
Methods: This is a descriptive study encompassing the
eriod between January and December, 2008. Complete
FV-ESAVI forms were included, after the expert commit-
ee evaluations. Adverse events were grouped using current
AHO/WHO classiﬁcation. Samples (serum, CSF and liver
iopsies) were processed at the INEVH through standard
echniques.
Vaccine shots: 1,806,400.
Results: Fifty ESAVIs were included:
lassiﬁcation Mild-Moderate Severe
12 2
a - -
b 23 9
- 1
The 2b severe ESAVIs consisted of eight YFV-AND and one
FV-VD, whereas the two severe type 1 ESAVIs consisted of
ne urinary sepsis and a sepsis-like case without ﬁnal diag-
osis. The type 3 ESAVI was an ADEM.
Neither reactions nor programmatic errors were
eported.
YFV-VD rate was 0.5/1.000.000 doses; YFV-AND
.4/1.000.000 doses No particular vaccine lot was
elated to ESAVIs. Global incidence of ESAVIs coincides
ith the heretofore published data. However, some of
he authors knew of more clinically compatible YFV-AND
nd VD non-studied cases, and there is strong suspicion of
nderreporting.
Conclusion: An accurate surveillance system and a refer-
nce laboratory are fundamental for ESAVIs study. Detailed
eports for valid conclusions and opportune actions, plus
multidisciplinary work for rigorous analysis is needed.
carefully managed risk-beneﬁt balance when prescribing
FV alongside with updated epidemiological information for
ccurate guidance is critical.
oi:10.1016/j.ijid.2010.02.629
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Background: BCG vaccine is the only preventive measure
gainst tuberculosis. At least two genomes from BCG, Pas-
eur and Japan, have been described. Evolutionary schemes
stablish by DU2 and other markers situated BCG Japan and
asteur into group I and IV from genealogy of BCG vac-
ines, respectively, classiﬁed as early and late strains. Some
CG such as Mexico 1931 is not included in any comparative
tudies based on phenotypic, genotyping, immune response
